Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Cutaneous Lymphoid Infiltrates in Patients Receiving Biologic Modifiers

  • Chapter
  • First Online:
Cutaneous Hematopathology

  • 1368 Accesses

Abstract

Major advancements in the treatment of cancer and immune-mediated diseases have been made over the past few decades with the introduction of a variety of new biologic and chemotherapeutic agents. Their use, however, has been associated with a variety of adverse cutaneous reactions, some of which may even lead to the discontinuation of the inciting therapy. In this chapter, the clinical and histologic features of the following reactions are discussed: granuloma annulare/interstitial granulomatous dermatitis and urticaria/cellulitis associated with tumor necrosis factor-alpha inhibitors, neutrophilic dermatoses associated with granulocyte colony-stimulating factor, injection site reactions of interferon, hand-foot skin reaction of kinase inhibitor (sorafenib, sunitinib), urticaria and infusion reactions of CD20 inhibitors, Richter’s syndrome associated with CD52 inhibitors, and pseudodermatomyositis associated with chronic hydroxyurea.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNF-alpha blockade. J Am Acad Dermatol. 2004;51(4):660–2.

    PubMed  Google Scholar 

  • Agesta N, Zabala R, Diaz-Perez JL. Alopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology. 2002;205(3):300–1.

    CAS  PubMed  Google Scholar 

  • Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211. doi:10.2165/11595240-000000000-00000.

    PubMed  Google Scholar 

  • Alonso-Perez A, Ballestero-Diez M, Fraga J, Garcia-Diez A, Fernandez-Herrera J. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma. J Eur Acad Dermatol Venereol. 2006;20(10):1328–9.

    CAS  PubMed  Google Scholar 

  • Alvarez-Ruiz S, Penas PF, Fernandez-Herrera J, Sanchez-Perez J, Fraga J, Garcia-Diez A. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004;18(3):310–3.

    CAS  PubMed  Google Scholar 

  • Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol. 2007;34 Suppl 1:18–21.

    PubMed  Google Scholar 

  • Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411–6. doi:10.1158/1078-0432.CCR-08-1141.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bahadoran P, Castanet J, Lacour JP, Perrin C, Del Giudice P, Mannocci N, et al. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases. Br J Dermatol. 1996;134(6):1161–3.

    CAS  PubMed  Google Scholar 

  • Baron S, Tyring SK, Fleischmann Jr WR, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266(10):1375–83.

    CAS  PubMed  Google Scholar 

  • Batycka-Baran A, Flaig M, Molin S, Ruzicka T, Prinz JC. Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. Expert Opin Drug Saf. 2012;11(6):911–21. doi:10.1517/14740338.2012.727796.

    CAS  PubMed  Google Scholar 

  • Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012;11:CD008079. doi:10.1002/14651858.CD008079.pub2.

    PubMed  Google Scholar 

  • Beard JS, Smith KJ, Skelton HG. Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic feature of graft-versus-host disease. J Am Acad Dermatol. 1993;29(2 Pt 2):325–30.

    CAS  PubMed  Google Scholar 

  • Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol. 2008;26(26):4355–6. doi:10.1200/JCO.2008.16.2933.

    PubMed  Google Scholar 

  • Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, Nuñez-Cornejo C, Casterá MD, Abad FJ. Urticaria due to etanercept in a patient with psoriatic arthritis. South Med J. 2009;102(3):304–5. doi:10.1097/SMJ.0b013e31819450e7.

    PubMed  Google Scholar 

  • Bouaziz JD, Ortonne N, Giustiniani J, Schiavon V, Huet D, Bagot M, Bensussan A. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients. J Invest Dermatol. 2005;125(6):1273–8.

    CAS  PubMed  Google Scholar 

  • Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006;154:880–4.

    CAS  PubMed  Google Scholar 

  • Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884–96.

    CAS  PubMed  Google Scholar 

  • Christian MM, Diven DG, Sanchez RL, Soloway RD. Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C. J Am Acad Dermatol. 1997;37(1):118–20.

    CAS  PubMed  Google Scholar 

  • Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176–86. doi:10.1080/02841860701765675.

    CAS  PubMed  Google Scholar 

  • Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol. 1994;130(10):1278–83.

    CAS  PubMed  Google Scholar 

  • Coca A, Sanz I. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol. 2012;24(5):451–6. doi:10.1097/BOR.0b013e32835707e4.

    CAS  PubMed  Google Scholar 

  • Cohen PR. Sweet’s syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.

    PubMed Central  PubMed  Google Scholar 

  • Cohen Y, Da’as N, Libster D, Amir G, Berrebi A, Polliack A. Large – cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication? Eur J Haematol. 2002;68(2):80–3.

    CAS  PubMed  Google Scholar 

  • Colombel JF, Loftus Jr EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19–31.

    CAS  PubMed  Google Scholar 

  • Couderc LJ, Philippe B, Franck N, Balloul-Delclaux E, Lessana-Leibowitch M. Necrotizing vasculitis and exacerbation of psoriasis after granulocyte colony-stimulating factor for small cell lung carcinoma. Respir Med. 1995;89(3):237–8.

    CAS  PubMed  Google Scholar 

  • Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003;48(3):439–41.

    PubMed  Google Scholar 

  • Dalmau J, Pimentel CL, Puig L, Peramiquel L, Roe E, Alomar A. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. J Am Acad Dermatol. 2005;53(1):62–6.

    PubMed  Google Scholar 

  • Demirturk N, Aykin N, Demirdal T, Cevik F. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-INF and ribavirin. Eur J Dermatol. 2006;16(5):579–80.

    PubMed  Google Scholar 

  • Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142(2):198–202.

    PubMed  Google Scholar 

  • Dereure O, Rason-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alpha and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147(6):1142–6.

    CAS  PubMed  Google Scholar 

  • Detmar U, Agathos M, Nerl C. Allergy of delayed type to recombinant interferon alpha 2c. Contact Dermatitis. 1989;20(2):149–50.

    CAS  PubMed  Google Scholar 

  • Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465–71.

    CAS  PubMed  Google Scholar 

  • Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333(8):487–93.

    CAS  PubMed  Google Scholar 

  • Errante D, Bernardi D, Bianco A, De Nardi S, Salvagno L. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. Ann Oncol. 2006;17(11):1720–1.

    CAS  PubMed  Google Scholar 

  • Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol. 2004;50(5 Suppl):S75–7.

    PubMed  Google Scholar 

  • Faguer S, Launay F, Ysebaert L, Mailhol C, Estines-Chartier O, Lamant L, Paul C. Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab. Br J Dermatol. 2007;157(4):841–2.

    CAS  PubMed  Google Scholar 

  • Fantini F, Padalino C, Gualdi G, Monari P, Giannetti A. Cutaneous lesions as initial signs of interferon alpha-induced sarcoidosis: report of three new cases and review of the literature. Dermatol Ther. 2009;22 Suppl 1:S1–7. doi:10.1111/j.1529-8019.2009.01263.x.

    PubMed  Google Scholar 

  • Fukutoku M, Shimizu S, Ogawa Y, Takeshita S, Masaki Y, Arai T, et al. Sweet’s syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anaemia. Br J Haematol. 1994;86(3):645–8.

    Google Scholar 

  • Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K. Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol. 2000;95(1):310–2.

    CAS  PubMed  Google Scholar 

  • González-López MA, Martínez-Taboada VM, González-Vela MC, Blanco R, Fernández-Llaca H, Rodríguez-Valverde V, Val-Bernal JF. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol. 2007;32(6):672–4.

    PubMed  Google Scholar 

  • Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51(4):653–62. doi:10.1093/rheumatology/ker290.

    CAS  Google Scholar 

  • Hagen JW, Magro CM, Crowson AN. Emerging adverse cutaneous drug reactions. Dermatol Clin. 2012;30(4):695–730. doi:10.1016/j.det.2012.06.016.

    CAS  PubMed  Google Scholar 

  • Hale G, Swirsky D, Waldmann H, Chan LC. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol. 1985;60(1):41–8.

    CAS  PubMed  Google Scholar 

  • Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol. 2008;26(5):546–53. doi:10.1016/j.clindermatol.2007.10.023.

    PubMed  Google Scholar 

  • Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89(8):1835–44.

    CAS  PubMed  Google Scholar 

  • Hertl MS, Haendle I, Schuler G, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol. 2005;152(3):552–5.

    CAS  PubMed  Google Scholar 

  • Isaacs A, Lindemann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–67.

    CAS  PubMed  Google Scholar 

  • Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210–1.

    CAS  PubMed  Google Scholar 

  • Jain KK. Cutaneous vasculitis associated with granulocyte colony-stimulating factor. J Am Acad Dermatol. 1994;31(2 Pt 1):213–5.

    CAS  PubMed  Google Scholar 

  • Jamroziak K, Grzybowska-Izydorczyk O, Jesionek-Kupnicka D, Gora-Tybor J, Robak T. Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine. Br J Haematol. 2012;158(2):286–8; author reply 289. doi:10.1111/j.1365-2141.2012.09127.x.

    CAS  PubMed  Google Scholar 

  • Janssens A, Berth M, De Paepe P, Verhasselt B, Van Roy N, Noens L, et al. EBV negative Richter’s syndrome from a coexistent clone after savage treatment with alemtuzumab in a CLL patient. Am J Hematol. 2006;81(9):706–12.

    PubMed  Google Scholar 

  • Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol. 1994;130(1):77–81.

    CAS  PubMed  Google Scholar 

  • Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia. 2006;20(12):2204–7.

    CAS  PubMed  Google Scholar 

  • Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354(19):2034–45.

    CAS  PubMed  Google Scholar 

  • Kawakami T, Ohashi S, Kawa Y, Takahama H, Ito M, Soma Y, Mizoguchi M. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140(5):570–4.

    CAS  PubMed  Google Scholar 

  • Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.

    CAS  PubMed  Google Scholar 

  • Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–61.

    CAS  PubMed  Google Scholar 

  • Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol. 1975;111(2):183–7.

    CAS  PubMed  Google Scholar 

  • Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for Hepatitis B. Eur J Dermatol. 2005;15(2):107–9.

    PubMed  Google Scholar 

  • Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6(3):165–74. doi:10.1038/nrrheum.2009.279.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kokudo N, Nakajima J, Hatano E, Numata K. Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). Clin Drug Investig. 2012;32 Suppl 2:25–35. doi:10.2165/1163023-S0-000000000-00000.

    CAS  PubMed  Google Scholar 

  • Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis. 1999;58 Suppl 1:I32–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2. doi:10.1001/archderm.144.6.820.

    PubMed Central  PubMed  Google Scholar 

  • Koontz D, Alshekhlee A. Embolia cutis medicamentosa following interferon beta injection. Mult Scler. 2007;13(9):1203–4.

    CAS  PubMed  Google Scholar 

  • Krainick U, Kantarjian H, Broussard S, Talpaz M. Local cutaneous necrotizing lesions associated with interferon injections. J Interferon Cytokine Res. 1998;18(10):823–7.

    CAS  PubMed  Google Scholar 

  • Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955–61. doi:10.1093/annonc/mdn389.

    CAS  PubMed  Google Scholar 

  • Lang AM, Norland AM, Schuneman RL, Tope WD. Localized interferon alfa-2b-induced alopecia. Arch Dermatol. 1999;135(9):1126–8.

    CAS  PubMed  Google Scholar 

  • Lee L, Kukreti V. Rituximab-induced coronary vasospasm. Case Rep Hematol. 2012;2012:984986. doi:10.1155/2012/984986.

    PubMed Central  PubMed  Google Scholar 

  • Lee A, Skelly ME, Kingma DW, Medeiros LJ. B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma. An unusual variant of Richter’s syndrome. Am J Clin Pathol. 1995;103(3):348–52.

    CAS  PubMed  Google Scholar 

  • Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51. doi:10.1111/j.1365-2133.2009.09290.x.

    CAS  PubMed  Google Scholar 

  • Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood. 2004;104(3):655–8.

    CAS  PubMed  Google Scholar 

  • Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy. Leuk Lymphoma. 1997;26(5–6):629–32.

    CAS  PubMed  Google Scholar 

  • Long D, Thiboutot DM, Majeski JT, Vasily DB, Helm KF. Interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol. 1996;34(6):957–61.

    CAS  PubMed  Google Scholar 

  • Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13(12):1948–50.

    CAS  PubMed  Google Scholar 

  • Luton K, Garcia C, Poletti E, Koester G. Nicolau syndrome: three cases and review. Int J Dermatol. 2006;45(11):1326–8.

    PubMed  Google Scholar 

  • Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25(2):72–8.

    CAS  PubMed  Google Scholar 

  • Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008–16. doi:10.1056/NEJMct1114348.

    CAS  PubMed  Google Scholar 

  • Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. Br J Haematol. 2006;132(1):115–6.

    PubMed  Google Scholar 

  • Montoto S, Bosch F, Estrach T, Blade J, Nomdedeu B, Nontserrat E. Pyoderma gangrenosum triggered by alpha2b-interferron in a patient with chronic granulocytic leukemia. Leuk Lymphoma. 1998;30(1–2):199–202.

    CAS  PubMed  Google Scholar 

  • Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol. 2004;140(2):215–7.

    PubMed  Google Scholar 

  • Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford). 2012;51(12):2252–61. doi:10.1093/rheumatology/kes217.

    CAS  Google Scholar 

  • Moustou AE, Matelovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486–504. doi:10.1016/j.jaad.2008.10.060.

    CAS  PubMed  Google Scholar 

  • Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225–34.

    CAS  PubMed  Google Scholar 

  • Omair MA, Alnaqbi KA, Lee P. Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature. Clin Rheumatol. 2012;31(8):1259–61. doi:10.1007/s10067-012-2002-8.

    PubMed  Google Scholar 

  • Oskay T, Kutluay L, Ozyilkan O. Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera. Eur J Dermatol. 2002;12(6):586–8.

    PubMed  Google Scholar 

  • Ostlere LS, Harris D, Prentice HG, Rustin MHA. Widespread folliculitis induced by human granulocyte-colony stimulating factor therapy [Letter]. Br J Dermatol. 1992;127:193.

    CAS  PubMed  Google Scholar 

  • Papi M, Didona B, DePita O, Abruzzese E, Stasi R, Papa G, Cavalieri R. Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea. J Am Acad Dermatol. 1993;28(3):485–6.

    CAS  PubMed  Google Scholar 

  • Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87–103.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Paydas S, Sahin B, Seyrek E, Soylu M, Gonlusen G, Acar A, Tuncer I. Sweet syndrome associated with G-CSF. Br J Dermatol. 1993;85(1):191–2.

    CAS  Google Scholar 

  • Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. J Eur Acad Dermatol. 2003;17(2):193–5.

    Google Scholar 

  • Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol. 2001;18(5):417–21.

    CAS  PubMed  Google Scholar 

  • Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet. 1986;1(8496):1466–8.

    CAS  PubMed  Google Scholar 

  • Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC. Regional squamous cell carcinomas following sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Arch Dermatol. 2010;146(12):1438–9. doi:10.1001/archdermatol.2010.367.

    PubMed  Google Scholar 

  • Reuss-Borst MA, Pawelec G, Saal JG, Horny HP, Müller CA, Waller HD. Sweet’s syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol. 1993;84(2):356–8.

    CAS  PubMed  Google Scholar 

  • Rey J, Wickenhauser S, Ivanov V, Coso D, Gastaut JA, Bouabdallah R. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma. J Eur Acad Dermatol Venereol. 2009;23(2):210. doi:10.1111/j.1468-3083.2008.02792.x.

    CAS  PubMed  Google Scholar 

  • Richard M, Truchetet F, Friedel J, Leclech C, Heid E. Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J Am Acad Dermatol. 1989;21(4 Pt 1):797–9.

    CAS  PubMed  Google Scholar 

  • Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4(4):285–92.7.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491–500.

    CAS  PubMed  Google Scholar 

  • Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177–82. doi:10.1097/CCO.0b013e3283436e8c.

    CAS  PubMed  Google Scholar 

  • Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol. 1993;11(10):1985–9.

    CAS  PubMed  Google Scholar 

  • Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7(11):664–75. doi:10.1038/nrrheum.2011.139.

    CAS  PubMed  Google Scholar 

  • Rocamora V, Puig L, Alomar A. Dermatomyositis-like eruption following hydroxyurea therapy. J Eur Acad Dermatol Venereol. 2000;14(3):227–8.

    CAS  PubMed  Google Scholar 

  • Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557–66. doi:10.1007/s00520-008-0409-1.

    CAS  PubMed  Google Scholar 

  • Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991;68(2):441–3.

    CAS  PubMed  Google Scholar 

  • Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27(1):1–10. doi:10.1002/hon.880.

    CAS  PubMed  Google Scholar 

  • Salihoglu A, Ozbalak M, Keskin D, Tecimer T, Soysal T, Ferhanoglu B. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease-case report. Transplant Proc. 2013;S0041-1345(12):1304–8. doi:10.1016/j.transproceed.2012.12.001.

    Google Scholar 

  • Sanders S, Busam K, Tahan SR, Johnson RA, Sachs D. Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. J Am Acad Dermatol. 2002;46(4):611–6.

    PubMed  Google Scholar 

  • Saraceno R, Teoli M, Chimenti S. Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. Clin Ther. 2008;30(7):1324–9.

    CAS  PubMed  Google Scholar 

  • Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs. 2006;7(5):451–6.

    CAS  PubMed  Google Scholar 

  • Senet P, Aractingi S, Porneuf M, Perrin P, Duterque M. Hydroxyurea-induced dermatomyositis-like eruption. Br J Dermatol. 1995;133(3):455–9.

    CAS  PubMed  Google Scholar 

  • Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15(4):380–6.

    CAS  PubMed  Google Scholar 

  • Shpiro D, Gilat D, Fisher-Feld L, Shemer A, Gold I, Trau H. Pyoderma gangrenosum successfully treated with perilesional granulocyte-macrophage colony stimulating factor. Br J Dermatol. 1998;138(2):368–9.

    CAS  PubMed  Google Scholar 

  • Sigal M, Crickx B, Blanchet P, Perron J, Simony J, Belaïch S. Cutaneous lesions induced by long-term use of hydroxyurea. Ann Dermatol Venereol. 1984;111(10):895–900 [Article in French].

    CAS  PubMed  Google Scholar 

  • Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol. 2012;24(3):284–90. doi:10.1097/CCO.0b013e328351c646.

    PubMed Central  PubMed  Google Scholar 

  • Skytta E, Phjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2000;18:533–4.

    CAS  PubMed  Google Scholar 

  • Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg. 2009;35(11):1766–70. doi:10.1111/j.1524-4725.2009.01289.x.

    CAS  PubMed  Google Scholar 

  • Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia. 1997;11(4):466–78.

    CAS  PubMed  Google Scholar 

  • Stasi R, Cantonetti M, Abruzzesse E, Papi M, Didona B, Cavalieri R, Papa G. Multiple skin tumors in long-term treatment with hydroxyurea. Eur J Dermatol. 1992;48(2):121–2.

    CAS  Google Scholar 

  • Stewart LR, George S, Hamacher KL, Hsu S. Granuloma annulare of the palms. Dermatol Online J. 2011;17(5):7.

    PubMed  Google Scholar 

  • Suehiro M, Kishimoto S, Wakabayashi T, Ikeuchi A, Miyake H, Takenaka H, et al. Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer. Br J Dermatol. 1998;139(4):748–9.

    CAS  PubMed  Google Scholar 

  • Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349–56.

    CAS  PubMed  Google Scholar 

  • Tai YJ, Tam M. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol. 2005;46(3):154–7.

    PubMed  Google Scholar 

  • Tohda S, Morio T, Suzuki T, Nagata K, Kamiyama T, Imai Y, et al. Richter syndrome with two B cell clones possessing different surface immunoglobulins and immunoglobulin gene rearrangements. Am J Hematol. 1990;35(1):32–6.

    CAS  PubMed  Google Scholar 

  • Tomasiewicz K, Modzewska R, Semczuk G. Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report. Adv Ther. 2006;23(1):139–42.

    PubMed  Google Scholar 

  • Valks R, Vargas E, Munoz E, Fernandez-Herrera J, Garcia-Diez A, Fraga J. Dermal infiltrate of enlarged macrophages in patients receiving chemotherapy. J Cutan Pathol. 1998;25(5):259–64.

    CAS  PubMed  Google Scholar 

  • Van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807–11.

    PubMed  Google Scholar 

  • van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2011;26(6):881–92. doi:10.1007/s00467-010-1717-5. Epub 2011 Jan 13.

    PubMed  Google Scholar 

  • van Kamp H, van den Berg E, Timens W, Kraaijenbrink RA, Halie MR, Daenen SM. Sweet’s syndrome in myeloid malignancy: a report of two cases. Br J Haematol. 1994;86(2):415–7.

    PubMed  Google Scholar 

  • Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):567–70.

    CAS  PubMed  Google Scholar 

  • Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome. J Am Acad Dermatol. 1996;34(5 Pt 2):918–23.

    CAS  PubMed  Google Scholar 

  • White JM, Mufti GJ, Salisbury JR, du Vivier AW. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol. 2006;31(2):206–7.

    CAS  PubMed  Google Scholar 

  • Wilhelm S, Chien DS. Bay 43-9006: preclinical data. Curr Pharm Des. 2002;8(25):2255–7.

    CAS  PubMed  Google Scholar 

  • Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011;50(5):619–25. doi:10.1111/j.1365-4632.2011.04871.x.

    PubMed  Google Scholar 

  • Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitis-like reaction to subcutaneous etanercept injection. Arch Dermatol. 2006;142:218–20.

    PubMed  Google Scholar 

  • Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217–24.

    CAS  PubMed  Google Scholar 

  • Zeltser R, Valle L, Tanck C, Holyst M, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001;137(7):893–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Harvard Medical School, Boston, MA, USA

    Jonathan J. Lee BA

  2. Department of Pathology, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Warren 820, Boston, MA, 02114, USA

    Mai P. Hoang MD

Authors
  1. Jonathan J. Lee BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mai P. Hoang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mai P. Hoang MD .

Editor information

Editors and Affiliations

  1. Department of Hematopathology, IHCFLOW Diagnostic Laboratory, Lutz, Florida, USA

    Hernani D. Cualing

  2. Department of Dermatology, Boston University School of Medicine, Roger Williams Medical Center, Providence, Rhode Island, USA

    Marshall E. Kadin

  3. Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

    Mai P. Hoang

  4. Pensacola and Atlanta Dermpath Diagnostics, University of South Florida College of Medicine, Tampa, Florida, USA

    Michael B. Morgan

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lee, J.J., Hoang, M.P. (2014). Cutaneous Lymphoid Infiltrates in Patients Receiving Biologic Modifiers. In: Cualing, H., Kadin, M., Hoang, M., Morgan, M. (eds) Cutaneous Hematopathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0950-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0950-6_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0949-0

  • Online ISBN: 978-1-4939-0950-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation